Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

OBJECTIVE: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52 weeks. METHODS: In SPIRIT-P1, biologic-naïve patients with active PsA were randomized to ixekizumab 80 mg every 4 weeks (IXEQ4W; N = 107) or every 2 weeks (IXEQ2W; N = 103) following a 160 mg startin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B, Strand, Vibeke, Kishimoto, Mitsumasa, Mease, Philip, Thaçi, Diamant, Birt, Julie, Lee, Chin H, Shuler, Catherine L, Lin, Chen-Yen, Gladman, Dafna D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152421/
https://www.ncbi.nlm.nih.gov/pubmed/29945203
http://dx.doi.org/10.1093/rheumatology/key161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152421/
https://www.ncbi.nlm.nih.gov/pubmed/29945203
http://dx.doi.org/10.1093/rheumatology/key161

Ejemplares similares